5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
Recruiting · NCT04288427 · Registry updated 2025-10-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Lower Urinary Tract Symptoms, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urological Manifestations, benign prostatic hyperplasia, male reproductive system disorder, prostate disorder, urinary system disorder, urinary tract obstruction | Recruiting | Not applicable | 2025-10-28 | NCT04288427 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beth Israel Deaconess Medical Center | 161 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 617 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |